Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prevotella is a genus of Gram-negative, obligately anaerobic, non-spore-forming bacteria that constitute a significant portion of the human microbiota, particularly in the oral cavity, gastrointestinal tract, and female reproductive tract (Wikipedia, 2023). While often existing as commensals, certain species such as Prevotella copri and Prevotella intermedia are frequently associated with inflammatory conditions, including rheumatoid arthritis, periodontitis, and bacterial vaginosis (NIH, 2021). As a genus, it is not a single molecular target like a receptor or enzyme but rather a biological taxon that may be modulated for therapeutic benefit. In clinical practice, Prevotella species are typically addressed through antimicrobial agents such as metronidazole or clindamycin when they act as pathogens in anaerobic infections (StatPearls, 2023). Recent research also explores the modulation of Prevotella levels through diet and probiotics to manage systemic inflammation and metabolic health.
Inhibition of DNA synthesis (Nitroimidazoles), inhibition of protein synthesis (Lincosamides), inhibition of cell wall synthesis (Beta-lactams)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prevotella.